BPC 157 (Body Protection Compound 157) is a synthetic peptide composed of 15 amino acids. Its amino acid sequence is Gly-Glu-Pro-Pro- Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This peptide segment was initially isolated from a natural protein in human gastric juice - pepsinogen C (PGC), and is named for its significant cell protection and tissue repair properties. The molecular weight of BPC 157 is approximately 1419 Daltons. It has a stable chemical structure and can be administered through various routes such as oral administration and injection.
BPC 157 Peptide Capsules, as a new type of bioactive peptide preparation, have shown broad application prospects in fields such as wound healing, gastrointestinal diseases, and neurological diseases. However, as it has not yet been officially approved as a drug, it is necessary to fully understand its potential risks before use and use it reasonably under the guidance of a professional doctor. In the future, with the in-depth research and the conduct of clinical trials, BPC 157 is expected to become a safe and effective therapeutic drug, bringing new hope to human health.
 |
 |
BPC-157 Powder COA
Mechanism of action
BPC 157 (Body Protection Compound 157) is a synthetic peptide composed of 15 amino acids, which has various biological activities and plays an important role in promoting tissue repair, anti-inflammation, neuroprotection, etc. BPC 157 Peptide Capsules are administered orally, and its mechanism of action mainly includes the following aspects:
Promote angiogenesis
BPC 157 can significantly promote the expression of vascular endothelial growth factor (VEGF) and accelerate the formation of new blood vessels. This process is crucial for wound healing and tissue repair. During the wound healing process, an adequate blood supply can provide the damaged tissue with the necessary oxygen and nutrients, promoting cell proliferation and migration. BPC 157 accelerates the reconstruction of microvessels in damaged tissues by activating the VEGF pathway, thereby improving local blood circulation and accelerating the healing speed.
Anti-inflammatory effect
BPC 157 has significant anti-inflammatory activity and can inhibit the release of pro-inflammatory cytokines (such as TNF-α, IL-6), thereby alleviating the inflammatory response. Inflammation is a defense response of the body to injury or infection, but an excessive inflammatory response can lead to tissue damage and delayed healing. BPC 157 helps alleviate symptoms such as inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis) by regulating the function of the immune system and reducing the production of inflammatory mediators. Furthermore, BPC 157 can further alleviate the inflammatory response by inhibiting the NF-κB signaling pathway and reducing the release of pro-inflammatory factors.
Cell protection and regeneration
BPC 157 can activate intracellular repair signaling pathways (such as Akt and ERK), promoting cell proliferation and migration. At the cellular level, BPC 157 can enhance the anti-damage ability of cells and promote the repair and regeneration of damaged tissues. For example, in the injury repair of connective tissues such as tendons and ligaments, BPC 157 can accelerate the synthesis of collagen, provide structural support for the tissues and promote healing. Furthermore, BPC 157 can further accelerate cell proliferation and migration by enhancing the phosphorylation levels of growth-related pathways such as EGFR, MAPK/ERK.
Neuroprotection and repair
BPC 157 has a protective effect on the nervous system and can promote the regeneration of neurons and the formation of synapses. After neurological injuries (such as spinal cord injury and stroke), BPC 157 can reduce the death of neurons and promote the recovery of neurological function. This mechanism of action may be related to the ability of BPC 157 to up-regulate the expression of genes such as Egr1 and Vegfr2, which play important roles in the growth and differentiation of neurons. Furthermore, BPC 157 can also have a positive impact on the central nervous system by improving the communication of the gut-brain axis and alleviate emotional disorders such as anxiety and depression.
Gastrointestinal protection
BPC 157 was originally isolated from gastric juice and has a protective effect on the gastrointestinal tract. It can promote the regeneration and repair of gastric mucosal cells, reduce the damage of gastric acid to the gastric mucosa, and thereby prevent and treat gastrointestinal diseases such as gastric ulcers. Furthermore, BPC 157 can also regulate the intestinal microbiota, improve intestinal barrier function, and alleviate symptoms such as irritable bowel syndrome (IBS).
Antioxidant stress
BPC 157 can activate antioxidant enzymes (such as SOD) and reduce oxidative stress damage. Oxidative stress is one of the important mechanisms for cell damage and disease occurrence. BPC 157 maintains the normal functions of cells by enhancing their antioxidant capacity and protecting them from the attack of free radicals.
Analysis of application in patients with digestive system diseases
BPC 157 (Body Protection Compound 157) is a synthetic peptide composed of 15 amino acids, which has significant gastrointestinal protection, anti-inflammatory and tissue repair properties. The potential application value of its oral capsule preparation (BPC 157 Peptide Capsules) in patients with digestive system diseases is mainly reflected in the following aspects:
Gastric Ulcer and Gastric Mucosa Protection
Mechanism of action
BPC 157 accelerates ulcer healing by promoting the proliferation, migration and angiogenesis of gastric mucosal cells. It can up-regulate the expressions of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), and enhance the mucosal barrier function. Animal experiments have shown that BPC 157 has significant therapeutic effects on alcohol, non-steroidal anti-inflammatory drugs (NSAIDs), and stress ulcer models, and its healing speed is superior to that of traditional drugs (such as cimetidine).
Clinical potential
Patients with gastric ulcers often experience recurrent conditions due to abnormal gastric acid secretion or impaired mucosal defense mechanisms. The anti-ulcer effect of BPC 157 does not rely on the acid-suppressing mechanism and may provide an alternative for patients who are resistant or intolerant to proton pump inhibitors (PPIs).
Adjuvant Therapy for Inflammatory Bowel Disease (IBD)
Anti-inflammatory and mucosal repair
BPC 157 can inhibit the release of pro-inflammatory cytokines (such as TNF-α and IL-6) and alleviate intestinal inflammation. It reduces intestinal permeability and promotes the regeneration of intestinal mucosal epithelial cells by regulating the NF-κB signaling pathway. In ulcerative colitis and Crohn's disease models, BPC 157 can reduce the area of intestinal wall ulcers and promote intestinal anastomotic healing..
Prevention of fistulas and stenosis
Patients with IBD are often accompanied by intestinal fistula or intestinal cavity stenosis. BPC 157 reduces the need for surgical intervention by promoting collagen synthesis and angiogenesis, accelerating the closure of fistulas and the repair of narrowed segments.
Irritable Bowel Syndrome (IBS) and leaky Gut Syndrome
Improvement of intestinal barrier function
BPC 157 can up-regulate the expression of tight junction proteins (such as Occludin and ZO-1), enhance the integrity of the intestinal barrier, and reduce bacterial and toxin translocation. It alleviates the symptoms of abdominal pain, diarrhea and constipation in patients with IBS by regulating the composition of the intestinal microbiota.
Intervention for leaky gut syndrome
Patients with leaky gut syndrome are prone to systemic inflammation due to increased intestinal permeability. BPC 157 reduces the risk of complications related to intestinal leakage by reducing oxidative stress and the release of inflammatory factors.
Hepatopancreas Protection and Metabolic Diseases
Relief of alcoholic liver injury
BPC 157 can alleviate alcohol-induced hepatocyte apoptosis and fibrosis. It protects the structure and function of hepatocytes by inhibiting oxidative stress and inflammatory responses.
The potential application of pancreatitis
Animal experiments have shown that BPC 157 can alleviate pancreatic edema and inflammatory cell infiltration in acute pancreatitis and promote pancreatic tissue repair.
Safety and Usage Suggestions
Security data
In animal experiments, BPC 157 did not show obvious toxicity, and the liver and kidney function indicators were normal. In the short-term clinical trial (4-8 weeks), the patients had good tolerance and no serious adverse reactions were observed. However, the long-term safety and potential drug interactions still need further research.
Usage suggestions
Dosage: It is recommended to start with 200-500 micrograms per day, taken orally in divided doses, for a course of 4-8 weeks.
Combination therapy: When used in combination with immunosuppressants or anticoagulant drugs, it is necessary to monitor inflammatory indicators and coagulation function.
Contraindicated groups: Pregnant women, lactating women and children are prohibited from using it. People with impaired liver or kidney function should use it with caution.
Limitations and Future Directions
Research Limitations
At present, clinical studies of BPC 157 mostly focus on small-sample trials, lacking evidence from large-scale, multi-center, randomized controlled trials (RCTS). Its mechanism of action has not been fully clarified, especially the metabolic pathways and targets in humans remain unclear.
Future research directions
Conduct RCT studies to verify its efficacy and safety in diseases such as IBD and gastric ulcers.
Explore the combined treatment regimens of BPC 157 with other drugs (such as biologics).
Study its mechanism of action in the regulation of intestinal flora and the communication of the gut-brain axis.
Summary
BPC 157 Peptide Capsules have shown significant potential value in patients with digestive system diseases, especially having unique advantages in the treatment of gastric ulcers, IBD and leaky gut syndrome. Through its multi-target mechanism of action (anti-inflammation, mucosal repair, angiogenesis), it provides a new option for patients who are ineffective or intolerant to traditional treatments. However, due to the insufficiency of clinical evidence, it cannot be used as a first-line treatment drug at present. In the future, high-quality research needs to be further carried out to clarify its clinical positioning and safety, so as to promote its rational application in digestive system diseases.
Hot Tags: bpc 157 peptide capsules, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Melanotan ii powder, dermorphin peptide, DERMORPHIN, Cosmetic, dermorphin in humans